Updated · November 2026 · 112 studies

Research Library

The trials that changed what the field could claim, the safety work every trial rests on, and the null results that get left out of headlines. Each one is summarised in plain language and linked to the paper.

How to read this library

Clinical trials happen under careful screening, calibrated doses, and professional support, conditions that don’t transfer automatically to other contexts. Positive findings are evidence of what’s possible under those conditions, not a promise. Null and cautionary results are here on purpose.

Psilocybin Depression 2026

Efficacy and safety of psilocybin in treatment-resistant major depression: the EPISODE randomized clinical trial

A triple-blind German trial in 144 people with treatment-resistant depression missed its primary endpoint: 17% responded to 25 mg psilocybin at six weeks, against 10.6% on an active placebo, a gap that could be chance. Average symptom scores did fall more on psilocybin, but suicidal thoughts on dosing days were more common (4% against 1–2%), and one person developed lasting visual disturbances (HPPD). The authors call the trial inconclusive.

Mertens et al. · JAMA Psychiatry DOI 
Psilocybin Depression 2026

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

A trial run inside England’s NHS: 60 people with treatment-resistant depression had a single 25 mg dose or a placebo, each with preparation and integration support. Depression scores were about 10 points lower on psilocybin at three weeks, and the gap held at six. Mild side effects were more common on psilocybin (164 against 123). It was designed to test whether a larger trial is workable, not to prove the treatment works.

Rucker et al. · Nature Medicine DOI 
Psilocybin Addiction 2026

Psilocybin or nicotine patch for smoking cessation: a pilot randomized clinical trial

The randomised follow-up to the 2014 smoking pilot: 82 smokers had either one high dose of psilocybin or a nicotine patch, both alongside 13 weeks of cognitive behavioural therapy. At six months, 40.5% of the psilocybin group had stayed off cigarettes, confirmed by testing, against 10% on the patch. Nobody was blinded, and everyone was screened as psychiatrically healthy.

Johnson, Naudé, Hendricks & Garcia-Romeu · JAMA Network Open DOI 
Psilocybin Addiction 2026

Psilocybin in the treatment of cocaine use disorder: a randomized clinical trial

The first randomised trial of psilocybin for cocaine use disorder, in 40 people in Alabama, most of them Black men on low incomes, a group rarely included in this research. One dose with therapy, against an active placebo, was followed by more cocaine-free days and a lower risk of relapse over six months, with no serious adverse events. With only 40 people, the true size of the effect is very uncertain.

Hendricks et al. · JAMA Network Open DOI 
Psilocybin Depression 2026

Short-term and late-term effects of psilocybin on symptoms in major depression: a randomized clinical trial

A Stockholm trial that followed 35 people with recurrent depression for a full year after one 25 mg dose or an active placebo. Psilocybin’s advantage was clear at one, two and six weeks, but by twelve months the two groups no longer differed. Two people on psilocybin had persistent, severe anxiety that needed medical attention.

Yngwe et al. · JAMA Network Open DOI 
Psilocybin Setting 2026

Psychedelics align brain activity with context

The largest single-site psychedelic brain-imaging study so far: 62 adults scanned at rest and during meditation, music and a film, before and on psilocybin. Rather than simply scrambling the brain, psilocybin organised its activity around what was happening around the person. The closer that alignment, the deeper the sense of dissolving into the surroundings and the bigger the change in mindset the next day. Evidence from the brain itself for why setting matters.

Stoliker et al. · Nature DOI 
MDMA PTSD 2026

Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: a systematic review and meta-analysis of clinical and functional outcomes

A meta-analysis of the randomised trials up to August 2025, eight of them with usable data. MDMA-assisted therapy reduced PTSD symptoms substantially and may improve day-to-day functioning, but did not clearly help depression. Most trials had a high risk of bias in how outcomes were measured, few used an active placebo, and the authors rate the certainty of the evidence as very low.

Fares-Otero et al. · European Neuropsychopharmacology DOI 
MDMA Memory 2026

Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: a systematic review and meta-analysis

A review of studies of people who had stopped using ecstasy for at least six months. Both current and former users did worse on learning and memory than people who had never used it, and longer abstinence brought no further recovery. The evidence is low quality, but it describes recreational ecstasy of unknown dose and purity, which is what most people take.

Ung et al. · Journal of Psychopharmacology DOI 
DMT Depression 2026

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial

The first placebo-controlled trial of DMT for depression: 34 adults had a 10-minute intravenous infusion of 21.5 mg DMT or placebo, with therapeutic support. Two weeks later, depression scores were about 7 points lower on DMT. In the open-label phase that followed, benefits lasted up to three months whether people had one dose or two. No serious adverse events.

Erritzoe et al. · Nature Medicine DOI 
5-MeO-DMT Depression 2026

Single intranasal administration of the psychedelic mebufotenin for treatment-resistant depression: a randomized clinical trial

The largest 5-MeO-DMT trial so far: 193 people with treatment-resistant depression at 38 sites took one nasal dose of 8 or 12 mg, or a token 0.3 mg comparison dose, with psychological support. After four weeks, depression scores had fallen 5 to 6 points more on the full doses, and about a third responded, against 12% on the low dose. Most people were ready to leave the clinic within two hours. Side effects were common but almost all mild or moderate.

Feifel et al. · JAMA DOI 
5-MeO-DMT Depression 2026

GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial

The follow-up to the 2021 safety study of inhaled 5-MeO-DMT: 81 people with treatment-resistant depression had up to three escalating inhaled doses in a single day, or placebo. A week later, 57.5% of the GH001 group were in remission against none on placebo, with no serious adverse events. The placebo-controlled period lasted only seven days, and an experience this intense is very hard to blind.

Cubała et al. · JAMA Psychiatry DOI 
Cannabis Adolescents 2026

Adolescent cannabis use and risk of psychotic, bipolar, depressive, and anxiety disorders

Following 463,396 Californian teenagers into their twenties: those who reported cannabis use in the past year were about twice as likely to be diagnosed later with a psychotic or bipolar disorder, and somewhat more likely to be diagnosed with depression or anxiety. The links held, slightly weaker, after adjusting for alcohol, other drugs and earlier mental-health problems.

Young-Wolff et al. · JAMA Health Forum DOI 
Microdosing Evidence review 2026

Classical psychedelic microdosing, mood, and cognitive function: an umbrella review with narrative synthesis

A review of the reviews up to February 2026, drawing on 14 studies and 1,614 people. The only consistent result from controlled studies was a small drop in cognitive control, the opposite of what microdosing is said to do. Mood benefits largely disappear once placebo is controlled for, and long-term risks, including heart effects linked to the 5-HT2B receptor, have not been studied.

Özaydın & Canlan Özaydın · Journal of Psychopharmacology DOI 
Microdosing Placebo effects 2026

Cognitive and subjective effects of psilocybin microdosing: results from two double-blind placebo-controlled longitudinal trials

Two double-blind trials of microdosing psilocybin truffles in everyday settings, testing focus, memory, social understanding and wellbeing. Once the results were corrected for the number of comparisons, microdosing did nothing measurable beyond placebo, though it did bring more unpleasant bodily feelings. Participants could not tell which they were taking.

Prochazkova et al. · Neuropharmacology DOI 
General HPPD 2026

Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study

Health records for 25,778 people diagnosed with hallucinogen persisting perception disorder, the largest study of the condition so far. Many already had depression (29.2%) or anxiety (26.2%) before diagnosis, and among psychedelic users, existing anxiety predicted who went on to develop it. HPPD was followed by more physical and psychiatric problems than in psychedelic users without it.

Butler et al. · Translational Psychiatry DOI 
General Support lines 2026

The Fireside Database: large-scale evidence from 25,419 psychedelic support interactions

The first large dataset from a psychedelic support line: 25,419 conversations with Fireside Project volunteers between 2021 and 2026. Psilocybin came up most often (59.9% of coded contacts), but cannabis had the highest rate of distress (47.2%). Mainly a resource for future research, and a reminder that cannabis, often treated as the mild option, was the substance most tied to distress among people who reached out.

Schoeller et al. · Science Advances DOI 
General Blinding 2026

Blinding integrity in psychedelic randomized clinical trials: a systematic review

Of 112 randomised trials of psychedelics for mental-health conditions, fewer than a third checked whether people could tell what they had been given. Where it was checked, psilocybin, LSD and ayahuasca trials often found blinding had failed for more than 90% of participants and raters. No placebo design reliably kept the trials blind, which is why their effect sizes deserve caution.

Orsini et al. · JAMA Psychiatry DOI 
General Adverse events 2026

Adverse health outcomes of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT

A nationally weighted US survey of 1,964 adults who had used one of five substances in the past year. Health problems people put down to the drug were far more common after ibogaine and 5-MeO-DMT: 74.2% of ibogaine users had needed health care because of it, against 16.2% for psilocybin, and 44.2% of recent ibogaine users and 51.3% of 5-MeO-DMT users reported heart palpitations or chest pain. Self-reported, with small ibogaine and 5-MeO-DMT groups and wide margins of error, but the gap is large.

Simonsson et al. · JAMA Network Open DOI 
Psilocybin Placebo effects 2025

Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis

Across 17 depression trials, people given psilocybin, SSRIs or esketamine improved by roughly similar amounts. The difference was in the control groups: people on placebo improved far less in psilocybin trials, one likely reason being that most can tell when they haven’t had a psychedelic. The authors conclude that psilocybin’s advantage over standard antidepressants may be overstated.

Hieronymus, López, Werin Sjögren & Lundberg · JAMA Network Open DOI 
Psilocybin Addiction 2025

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

A null result to set beside the 2022 alcohol trial. In 37 people who had just finished alcohol withdrawal treatment, one 25 mg dose with five therapy sessions did no better than placebo at preventing relapse or reducing drinking, at four weeks or at six months. Craving fell a little more on psilocybin. The authors suggest one dose may not be enough for people this severely affected.

Rieser et al. · eClinicalMedicine DOI 
Psilocybin End-of-life distress 2025

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: a phase 2b randomized controlled trial

An Australian palliative-care trial that tests the 2016 cancer findings in a new setting: 35 adults with a life-threatening illness had 25 mg psilocybin or an active placebo, with nine therapy sessions around it. Depression and anxiety fell more on psilocybin at six to seven weeks and stayed lower at 26 weeks. No serious adverse events; one person withdrew because of anxiety during the session.

Ross et al. · General Hospital Psychiatry DOI 
Psilocybin Suicidality 2025

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis

Nine randomised trials, 593 people: psilocybin therapy produced a small reduction in suicidal thoughts compared with control. No study reported a suicide attempt or death, but most never measured them, and the trials were small with short follow-up. Read it alongside the EPISODE trial, where suicidal thoughts on dosing days rose.

Wong et al. · Therapeutic Advances in Psychopharmacology DOI 
LSD Anxiety 2025

Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial

The largest LSD trial to date: 198 adults with generalised anxiety disorder took one dose of a pharmaceutical LSD (25 to 200 µg) or placebo, with no therapy attached. At four weeks, the 100 and 200 µg doses lowered anxiety scores by 5 to 6 points more than placebo; the lower doses did not separate. Almost everyone on the higher doses had visual effects, and nausea was common. The results are guiding the doses for phase 3.

Robison et al. · JAMA DOI 
Microdosing ADHD 2025

Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial

In a double-blind trial, 53 adults with ADHD took 20 µg LSD or placebo twice a week for six weeks. Both groups improved substantially, placebo slightly more, and LSD was no better. It was safe and well tolerated, so the problem was that it didn’t work, not that it did harm.

Mueller et al. · JAMA Psychiatry DOI 
General Psychosis risk 2025

Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder

Across 9 million people in Ontario, those who went to an emergency department because of hallucinogens were far more likely to be diagnosed with schizophrenia or a related disorder within three years: 3.99% against 0.15% of the general population, and still about 3.5 times as likely after accounting for other drug use and mental-health history. Observational, so it cannot show the drug caused the illness, but it is the clearest population-level warning sign so far.

Myran et al. · JAMA Psychiatry DOI 
General Psychosis risk 2025

Psychedelic use and psychiatric risks

A survey of 2,822 US adults, weighted to match the population. Psychedelic use was linked to more unusual visual experiences over a lifetime, and 1.3% of users had been told by a professional that they had HPPD. Recent psychotic symptoms were highest among people who had used psychedelics and had a family history of psychosis or bipolar disorder, and lowest among users without that history. A snapshot rather than a follow-up, but it is part of why family history matters.

Simonsson et al. · Psychopharmacology DOI 
General HPPD 2025

Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use

Followed 654 people from a week before a planned psychedelic experience to four weeks after. Over 30% reported lingering perceptual changes of the HPPD type at four weeks, but fewer than 1% found them distressing. Younger age, being female, a past psychiatric diagnosis and a tendency to become deeply absorbed predicted them. Delusional thinking scores fell a month after the experience.

Zhou, de Wied, Carhart-Harris & Kettner · PNAS Nexus DOI 
General Facilitator misconduct 2025

Psychedelic therapist sexual misconduct and other adverse experiences among a sample of naturalistic psychedelic users

An anonymous survey of 1,221 people who use psychedelics. Most had been frightened at some point during an experience (74.3%), and one in ten had a physical reaction. 8% said that they, or someone they knew, had experienced inappropriate sexual contact from a sitter, guide or practitioner. A convenience sample that includes second-hand reports, so not a prevalence rate, but a clear reason to vet anyone who will sit with you.

Kruger et al. · Psychedelic Medicine DOI 
Nature Nature relatedness 2025

Effects of ayahuasca on gratitude and relationships with nature: a prospective, naturalistic study

54 people surveyed before and after an ayahuasca retreat reported more gratitude and a stronger connection to nature at one week and one month. Awe and mystical-type experiences went with bigger changes; the number of ceremonies attended did not. Small and uncontrolled, but measured before and after rather than recalled.

Aday et al. · Journal of Psychoactive Drugs DOI 
Psilocybin Depression 2024

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

Pooling seven randomised trials (436 people), psilocybin beat placebo or an inactive comparator by a moderate margin. The effect was larger when depression came alongside another illness such as cancer, when people rated their own symptoms, and when they had taken psychedelics before, which points to expectation as part of the effect. The paper was corrected in 2025 after calculation errors; the corrected figures are the ones that stand.

Metaxa & Clarke · BMJ DOI 
Psilocybin Mechanism 2024

Psilocybin desynchronizes the human brain

A handful of healthy adults were each scanned about 18 times, before, during and for three weeks after 25 mg psilocybin and a stimulant comparison. Psilocybin disrupted the brain’s usual network patterns more than three times as much as methylphenidate, most of all in the default mode network, and the size of the change tracked how strong the experience felt. A weaker link between the hippocampus and that network lasted for weeks. Very few people, studied in great depth.

Siegel et al. · Nature DOI 
Psilocybin Bipolar disorder 2024

Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial

The first psilocybin trial in bipolar depression, a group nearly every other trial excludes. Fifteen people with bipolar II, taken off their medication, had one 25 mg dose with therapy; 12 were in remission at the end of the study, and mania and suicidality scores did not rise. It was open-label, uncontrolled and tiny, and bipolar I was not studied, so it does not change the standard caution about bipolar disorder.

Aaronson et al. · JAMA Psychiatry DOI 
Psilocybin Young people 2024

Psilocybin exposures reported to U.S. poison centers: national trends over a decade

US poison-centre reports involving psilocybin among 13- to 25-year-olds were flat from 2013 to 2018, then rose from 2019; by 2022 they had more than tripled among adolescents and more than doubled among young adults. About three in four single-substance cases needed medical attention. It counts reported exposures, so it cannot say why they rose.

Farah, Kerns, Murray & Holstege · Journal of Adolescent Health DOI 
Psilocybin Expectancy 2024

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression

A counterpoint to the blinding critiques. In the 2021 psilocybin-versus-escitalopram trial, patients expected more from psilocybin, yet expectation predicted who improved on escitalopram, not on psilocybin. What did predict response to psilocybin was a trait: how suggestible people were to begin with. A secondary analysis of 55 people.

Szigeti et al. · Psychological Medicine DOI 
MDMA Research integrity 2024

Retraction note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

In August 2024 the journal retracted this pooled analysis of the phase 2 MDMA trials, along with two companion papers, over protocol violations amounting to unethical conduct at one study site, which the authors knew of and did not disclose, and an undeclared competing interest. It came the same week the FDA declined to approve MDMA-assisted therapy. The two phase 3 trials (Mitchell 2021 and 2023) were not retracted.

Mithoefer et al. · Psychopharmacology DOI 
Ibogaine Brain injury 2024

Magnesium–ibogaine therapy in veterans with traumatic brain injuries

Stanford observational study of special-operations veterans treated in Mexico: one magnesium-ibogaine session was followed by large improvements in PTSD, depression, anxiety, and disability, with no cardiac events under monitoring.

Cherian et al. · Nature Medicine DOI 
General Adverse events 2024

Adverse events in studies of classic psychedelics: a systematic review and meta-analysis

The largest review of what goes wrong in psychedelic research: 114 studies and 3,504 participants. Serious adverse events happened to none of the healthy volunteers but to about 4% of people with an existing psychiatric condition, including worsening depression, suicidal behaviour, psychosis and seizures. Fewer than a quarter of recent studies looked for harms systematically, so the real rates may be higher.

Hinkle, Graziosi, Nayak & Yaden · JAMA Psychiatry DOI 
Psilocybin Depression 2023

Single-dose psilocybin treatment for major depressive disorder

A rigorous randomized trial with an active placebo (niacin): a single 25 mg dose with psychological support produced a large, sustained reduction in depression over six weeks.

Raison et al. · JAMA DOI 
Psilocybin Anorexia 2023

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

A first safety test in 10 women with anorexia, each given one 25 mg dose with psychological support. There were no clinically significant changes in heart rhythm, vital signs or suicidality; two developed low blood sugar without symptoms, which resolved within a day. It was built to show the treatment could be given safely, so it says nothing yet about whether it helps.

Peck et al. · Nature Medicine DOI 
Psilocybin Bipolar disorder 2023

Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of ‘magic mushroom’ consumption

The largest survey of people with bipolar disorder who have taken mushrooms (541 respondents). A third reported new or worsening symptoms after a trip, most often mania, sleep problems and anxiety, with no difference between bipolar I and II, and 3.3% needed emergency services. Most still rated mushrooms as more helpful than harmful; the authors call for close monitoring of symptoms in any trial.

Morton et al. · Journal of Psychopharmacology DOI 
Psilocybin Drug interactions 2023

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

From over 600 reports of taking mushrooms while on an antidepressant: SSRIs and SNRIs weakened the effects about half the time, bupropion less often. After stopping an SSRI or SNRI, weaker effects were still reported up to three to six months later. Retrospective self-report, so treat the numbers as rough.

Gukasyan et al. · Journal of Psychopharmacology DOI 
MDMA PTSD 2023

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

The confirmatory Phase 3 trial replicated the first in a more diverse sample. Despite both trials meeting endpoints, the FDA declined approval in 2024 and requested an additional study.

Mitchell et al. · Nature Medicine DOI 
LSD Anxiety 2023

Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness

Modern randomized trial of LSD for anxiety disorders: two 200 µg sessions produced rapid, robust reductions in anxiety and depression sustained at 16 weeks.

Holze et al. · Biological Psychiatry DOI 
DMT Mechanism 2023

Human brain effects of DMT assessed via EEG-fMRI

Simultaneous EEG-fMRI during the DMT peak: profound disintegration of higher-level cortical networks with increased global connectivity — the most detailed picture yet of a psychedelic’s acute brain action.

Timmermann et al. · PNAS DOI 
Mescaline Pharmacology 2023

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

The first modern head-to-head comparison: 32 healthy volunteers took mescaline, LSD (100 µg), psilocybin (20 mg) and placebo on separate days. At 500 mg, mescaline felt much like the other two, but it lasted longest: 11.1 hours on average, against 8.2 for LSD and 4.9 for psilocybin. Mescaline brought slightly more after-effects in the 12 to 24 hours that followed.

Ley et al. · Neuropsychopharmacology DOI 
Ketamine Depression 2023

Ketamine versus ECT for nonpsychotic treatment-resistant major depression

The largest head-to-head comparison: 403 people with treatment-resistant depression were assigned to ketamine infusions or electroconvulsive therapy for three weeks. Ketamine did at least as well (55.4% responded, against 41.2%) and spared memory, which dropped after ECT before gradually recovering. Open-label, so patients knew which treatment they had.

Anand et al. · New England Journal of Medicine DOI 
Ketamine Depression 2023

Esketamine nasal spray versus quetiapine for treatment-resistant depression

A phase 3 trial in 676 people with treatment-resistant depression, comparing esketamine nasal spray with quetiapine, a standard add-on, both alongside an SSRI or SNRI. At eight weeks, 27.1% were in remission on esketamine against 17.6% on quetiapine. Better, but most people on either treatment were not in remission. Open-label and funded by esketamine’s maker.

Reif et al. · New England Journal of Medicine DOI 
Ketamine Expectancy 2023

Randomized trial of ketamine masked by surgical anesthesia in patients with depression

40 people with depression who were already having surgery got ketamine or saline while under general anaesthesia, so nobody could feel which they had received. Ketamine did no better than placebo over the next three days. One small trial, but it raises the question of how much of ketamine’s rapid effect depends on knowing you have taken it.

Lii et al. · Nature Mental Health DOI 
2C-B Pharmacology 2023

Assessment of the acute effects of 2C-B vs. psilocybin on subjective experience, mood, and cognition

The first placebo-controlled study of 2C-B: 22 experienced volunteers took 20 mg 2C-B, 15 mg psilocybin and placebo. 2C-B produced a clearly psychedelic state, with less dysphoria and ego dissolution than psilocybin, the same slowing and memory impairment, and a similar rise in blood pressure. Its effects mostly faded within six hours. Neither drug made people more empathic, despite 2C-B’s reputation.

Mallaroni et al. · Clinical Pharmacology & Therapeutics DOI 
Cannabis Psychosis risk 2023

Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis

Health records for nearly 10 million people in Ontario: 18.5% of those seen in an emergency department for drug-induced psychosis were diagnosed with schizophrenia or a related disorder within three years. Cannabis-induced psychosis carried the highest risk of any substance, and young men were most at risk. A psychotic episode after cannabis is a serious warning, not a one-off.

Myran et al. · JAMA Psychiatry DOI 
Cannabis Psychosis risk 2023

Association between cannabis use disorder and schizophrenia stronger in young males than in females

Danish national registers covering almost 7 million people over five decades. Cannabis use disorder was linked to schizophrenia in both sexes, but among 16- to 20-year-olds the link was about twice as strong in men. If the link is causal, the authors estimate that about 15% of schizophrenia cases in men in 2021 were attributable to cannabis use disorder, and around one in five among young men.

Hjorthøj et al. · Psychological Medicine DOI 
Microdosing Mood 2023

Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial

80 healthy men took 10 µg LSD or placebo every three days for six weeks, mostly at home. On dose days, people on LSD rated themselves happier, more energetic and more connected, even after accounting for their expectations, but nothing had changed by the end of the six weeks. Four people on LSD dropped out because of anxiety.

Murphy et al. · Biological Psychiatry DOI 
General Extended difficulties 2023

Extended difficulties following the use of psychedelic drugs: a mixed methods study

Accounts from 608 people whose difficulties lasted well beyond a psychedelic experience: anxiety and fear, existential struggle, feeling cut off from others, and a sense of unreality. For about a third the problems lasted over a year, and for a sixth more than three years. They tended to pass sooner when people knew what drug and dose they had taken, and a guided setting was linked to a narrower range of problems. A self-selected sample, so it shows what can happen, not how often.

Evans et al. · PLOS ONE DOI 
General Mechanism 2023

Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

Cell and mouse work suggesting that LSD and psilocin bind directly to TrkB, the receptor for the brain’s growth factor BDNF, about 1,000 times more strongly than conventional antidepressants do. In mice, the plasticity and antidepressant-like effects ran through TrkB, while the head twitch that stands in for tripping ran through 5-HT2A. Animal data only, but it raises the possibility of the benefit without the trip.

Moliner et al. · Nature Neuroscience DOI 
General Mechanism 2023

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Cell and rodent work showing that psychedelics promote neuron growth by activating serotonin 2A receptors inside the cell, not on its surface. Serotonin itself does not easily cross the cell membrane, which would explain why it doesn’t trigger the same rewiring. Preclinical, but it changes the picture of where psychedelics act.

Vargas et al. · Science DOI 
General Mechanism 2023

Psychedelics reopen the social reward learning critical period

In mice, several psychedelics reopened a developmental window for learning social rewards that normally closes after adolescence, and the window stayed open longer for drugs whose effects last longer in humans. Animal data, but it fits the idea that the weeks after an experience are a period of unusual openness, one reason integration matters.

Nardou et al. · Nature DOI 
Nature Nature relatedness 2023

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness

Pooling five datasets (3,817 people), only psilocybin use, and not LSD, mescaline, salvia, ketamine or ibogaine, reliably predicted feeling connected to nature, with weaker results for DMT. Among people who had only used psilocybin, more frequent use went with stronger nature relatedness. Cross-sectional, so it cannot separate the drug from the settings people choose for it.

Forstmann et al. · Journal of Psychopharmacology DOI 
Psilocybin Depression 2022

Single-dose psilocybin for a treatment-resistant episode of major depression

The largest psilocybin trial to date (233 participants, 22 sites): 25 mg significantly reduced treatment-resistant depression versus 1 mg control at three weeks, though effects waned in a subset and adverse events were not trivial.

Goodwin et al. · New England Journal of Medicine DOI 
Psilocybin Addiction 2022

Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo

In the first modern RCT for alcohol use disorder (93 participants), two psilocybin sessions within psychotherapy roughly halved heavy drinking days over 32 weeks compared with active placebo.

Bogenschutz et al. · JAMA Psychiatry DOI 
Psilocybin Depression 2022

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up

The one-year follow-up of the 2021 Johns Hopkins depression trial: of 24 people who had two psilocybin sessions with therapy, 75% were still responding and 58% were in remission at 12 months. No comparison group remained by then, so it shows the benefit can last for some people, not how reliably it does.

Gukasyan et al. · Journal of Psychopharmacology DOI 
Psilocybin Drug interactions 2022

Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects

A controlled look at the antidepressant question in healthy volunteers: after two weeks of escitalopram, 25 mg psilocybin produced the same positive mood effects, with less anxiety, fewer bad drug effects and fewer cardiovascular side effects than after placebo. Two weeks on the SSRI in healthy people, so it does not tell you what happens after months of treatment.

Becker et al. · Clinical Pharmacology & Therapeutics DOI 
Psilocybin Emergencies 2022

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

From the Global Drug Survey: of 9,233 people who had used mushrooms in the past year, 19 (0.2%) sought emergency treatment, about 0.06% per occasion. Panic and paranoia were the usual problems, and poor mindset, a bad setting and mixing substances were the reasons people gave. Young age was the only predictor, and all but one were back to normal within 24 hours.

Kopra et al. · Journal of Psychopharmacology DOI 
Psilocybin Therapeutic alliance 2022

Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression

From the psilocybin arm of the 2021 escitalopram trial (30 people): the stronger the bond with the therapists, the more likely people were to have an emotional breakthrough or a mystical-type experience, and the lower their depression scores at the end. A weaker bond going into the second dose predicted worse outcomes in its own right. Correlational, but it suggests the relationship with whoever sits with you shapes both the experience and what follows.

Murphy et al. · Frontiers in Pharmacology DOI 
Ayahuasca Adverse effects 2022

Adverse effects of ayahuasca: results from the Global Ayahuasca Survey

From the Global Ayahuasca Survey of 10,836 people in more than 50 countries: 69.9% had physical effects, mostly vomiting, and 2.3% needed medical attention afterwards. 55.9% had difficult mental-health effects in the following weeks or months, which most saw as part of a growth process, though about 12% sought professional help. Physical problems were more likely in unsupervised settings and among heavier users; mental-health problems were more likely with an anxiety disorder.

Bouso et al. · PLOS Global Public Health DOI 
Ibogaine Cardiac risk 2022

Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study

14 people with opioid use disorder were given one 10 mg/kg dose of ibogaine under hospital monitoring in the Netherlands. The QTc interval, a measure of heart rhythm, lengthened by 95 ms on average, and half the group passed 500 ms, the range where dangerous arrhythmias become a real risk; in six people it stayed raised beyond 24 hours. Every participant had severe temporary loss of coordination and could not walk unaided. No arrhythmias occurred, with the heart monitored throughout.

Knuijver et al. · Addiction DOI 
Salvia Mechanism 2022

The kappa opioid receptor and the sleep of reason: cortico-subcortical imbalance following salvinorin-A

Two placebo-controlled studies of inhaled salvinorin A that measured brain activity and blood flow. Blood flow dropped across most of the cortex and rose in deeper regions, including the amygdala and hippocampus. The effects were intense and plainly dissociative, and nobody reported dysphoria.

Ona et al. · International Journal of Neuropsychopharmacology DOI 
Cannabis Potency 2022

Association of cannabis potency with mental ill health and addiction: a systematic review

The first systematic review of THC strength and mental health, covering 20 studies. Higher-potency cannabis was linked to a greater risk of psychosis and of cannabis use disorder; the evidence on depression and anxiety was mixed. The studies are observational and measure potency inconsistently, but they point the same way as the EU-GEI findings.

Petrilli et al. · The Lancet Psychiatry DOI 
Cannabis Hyperemesis 2022

Changes in emergency department visits for cannabis hyperemesis syndrome following recreational cannabis legalization and subsequent commercialization in Ontario, Canada

Emergency visits for cannabis hyperemesis syndrome, the cycles of severe vomiting tied to heavy, frequent use, rose 13-fold in Ontario between 2014 and 2021, and 8.8% of visits ended in a hospital admission. Legalisation itself brought no jump; the rise came as stores and products multiplied, a period that overlapped with the pandemic.

Myran et al. · JAMA Network Open DOI 
Microdosing Placebo effects 2022

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Double-blind study in a natural setting: acute measures showed subtle perceptible effects, but cognitive, creative, and wellbeing outcomes did not separate from placebo.

Cavanna et al. · Translational Psychiatry DOI 
Microdosing Observational 2022

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

The largest observational microdosing study: 953 people microdosing psilocybin and 180 who weren’t, followed for about a month. Microdosers reported small to medium improvements in mood and mental health. Nobody was blinded and people chose whether to microdose, so expectation can’t be ruled out, which is exactly what the placebo-controlled trials test.

Rootman et al. · Scientific Reports DOI 
Nature Pro-environmental behavior 2022

The relationship between psychedelic use, mystical experiences, and pro-environmental behaviors

Among 240 psychedelic-experienced participants, mystical-type experiences specifically — not use alone — predicted pro-environmental behavior, suggesting the quality of the experience drives the ecological shift.

Paterniti, Bright & Gringart · Journal of Humanistic Psychology DOI 
Psilocybin Depression 2021

Trial of psilocybin versus escitalopram for depression

Head-to-head against a standard SSRI over six weeks, psilocybin therapy performed at least as well on the primary measure and better on most secondary measures — though the trial was not powered to establish superiority.

Carhart-Harris et al. · New England Journal of Medicine DOI 
Psilocybin Depression 2021

Effects of psilocybin-assisted therapy on major depressive disorder

Randomized waiting-list trial in major depression: two psilocybin sessions with supportive therapy produced large, rapid antidepressant effects, with over half of participants in remission at four weeks.

Davis et al. · JAMA Psychiatry DOI 
MDMA PTSD 2021

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

The first Phase 3 trial: 67% of participants receiving MDMA-assisted therapy no longer met PTSD diagnostic criteria after three sessions, versus 32% with placebo plus identical therapy.

Mitchell et al. · Nature Medicine DOI 
MDMA Addiction 2021

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder

The first study of MDMA therapy for addiction: 14 people with alcohol use disorder had two MDMA sessions within eight weeks of recovery-focused therapy after detox. It was well tolerated, and nine months later they averaged 18.7 units of alcohol a week, down from 130.6 before detox. No control group, so it shows the treatment can be given safely, not that it works.

Sessa et al. · Journal of Psychopharmacology DOI 
5-MeO-DMT Depression 2021

A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001)

First formal Phase 1 trial of vaporized 5-MeO-DMT: single doses were tolerated in healthy volunteers with rapid, short-lived, dose-dependent peak experiences.

Reckweg et al. · Frontiers in Pharmacology DOI 
Mescaline Naturalistic use 2021

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

The largest survey of mescaline use to date: most respondents reported lasting improvements in depression, anxiety and problematic substance use. Self-reported and retrospective, so it shows what users say, not what the drug did.

Agin-Liebes et al. · ACS Pharmacology & Translational Science DOI 
Microdosing Placebo effects 2021

Self-blinding citizen science to explore psychedelic microdosing

The largest placebo-controlled microdosing study (191 participants self-blinding their own doses): microdosers improved on wellbeing measures — but so did placebo, with no significant difference between them.

Szigeti et al. · eLife DOI 
General Drug interactions 2021

Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports

In 62 online trip reports from people taking lithium with a classic psychedelic, 47% described seizures and 39% involved medical attention; none of 34 reports involving lamotrigine described a seizure. Anecdotal reports rather than a trial, but the signal is stark enough that lithium and psychedelics belong on the list of dangerous combinations.

Nayak et al. · Pharmacopsychiatry DOI 
General Group setting 2021

Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness

Surveyed 886 people at five points around psychedelic ceremonies and retreats. A sense of togetherness and shared humanity during the ceremony (“communitas”) predicted gains in wellbeing and social connection four weeks later, and a good relationship with facilitators helped it emerge. Observational, with no comparison group.

Kettner et al. · Frontiers in Pharmacology DOI 
DMT Entity encounters 2020

Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects

The largest survey of DMT entity encounters. Most respondents rated the experience among the most meaningful of their lives, and a majority came away believing the entity was real — including many who had held no such belief beforehand. Retrospective self-report from people who sought out the experience, so it describes a phenomenon rather than establishing its rate.

Davis et al. · Journal of Psychopharmacology DOI 
Ayahuasca Depression 2019

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

The first RCT of ayahuasca: a single session produced significant antidepressant effects versus placebo within a week in treatment-resistant patients.

Palhano-Fontes et al. · Psychological Medicine DOI 
Ketamine Depression 2019

Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression

A pivotal trial behind Spravato — the intranasal esketamine formulation that became the first psychedelic-adjacent medicine to win FDA approval (2019).

Popova et al. · American Journal of Psychiatry DOI 
Cannabis Safety 2019

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

Across eleven European sites, daily use of high-potency cannabis was associated with substantially raised odds of a first episode of psychosis, and differences in potency and frequency tracked differences in psychosis rates between cities. The strongest population-level evidence that potency and frequency matter.

Di Forti et al. · The Lancet Psychiatry DOI 
Microdosing Observational 2019

A systematic study of microdosing psychedelics

Six-week daily-diary study: small improvements in depression and stress and reduced mind-wandering, but effects were selective and did not match the sweeping claims of microdosing folklore.

Polito & Stevenson · PLOS ONE DOI 
General Mechanism 2019

REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics

The model most cited to explain how psychedelics work: relaxation of high-level beliefs (priors) allows bottom-up information to revise entrenched patterns of mind.

Carhart-Harris & Friston · Pharmacological Reviews DOI 
Nature Nature relatedness 2019

From egoism to ecoism: psychedelics increase nature relatedness in a state-mediated and context-dependent manner

Prospective study tracking people before and after planned psychedelic experiences: nature relatedness rose after use and stayed elevated at two years, mediated by ego dissolution and amplified by natural settings.

Kettner, Gandy, Haijen & Carhart-Harris · Int. Journal of Environmental Research and Public Health DOI 
5-MeO-DMT Naturalistic use 2018

The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption

Survey of 515 people who had used 5-MeO-DMT, most of them rarely and for spiritual reasons. Among those with a psychiatric diagnosis, most said their symptoms improved afterward (77% for depression, 69% for anxiety), and about a third reported challenging moments, mostly mild. Self-selected and retrospective, so it made the case for controlled trials rather than settling anything.

Davis, Barsuglia, Lancelotta, Grant & Renn · Journal of Psychopharmacology DOI 
Ibogaine Addiction 2018

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

Observational study of legal ibogaine treatment in New Zealand: a single treatment reduced opioid withdrawal and craving, with a subset achieving sustained abstinence at 12 months.

Noller, Frampton & Yazar-Klosinski · American Journal of Drug and Alcohol Abuse DOI 
Ibogaine Addiction 2018

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

Mexico clinic outcomes: ibogaine substantially reduced opioid withdrawal symptoms and use at follow-up — alongside a cardiac risk profile that makes medical screening and monitoring non-negotiable.

Brown & Alper · American Journal of Drug and Alcohol Abuse DOI 
2C-B Pharmacology 2018

Acute pharmacological effects of 2C-B in humans: an observational study

An observational study of 16 experienced users who took their own dose of 2C-B (10, 15 or 20 mg) while researchers measured the effects. It raised blood pressure and heart rate, brought euphoria and changes in how colours, shapes and distances looked, and in five people mild hallucinations. Small and uncontrolled, but one of very few human studies of 2C-B.

Papaseit et al. · Frontiers in Pharmacology DOI 
General Mechanism 2018

Psychedelics promote structural and functional neural plasticity

Preclinical foundation for the neuroplasticity hypothesis: psychedelics increased dendritic growth and synapse formation in cortical neurons, comparable to ketamine.

Ly et al. · Cell Reports DOI 
Nature Nature relatedness 2018

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression

In a clinical sample, nature relatedness increased significantly after psilocybin therapy and remained elevated at 7–12 months — evidence that the connection shift is a lasting effect, not an acute mood artifact.

Lyons & Carhart-Harris · Journal of Psychopharmacology DOI 
Nature Nature relatedness 2017

Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness

In a large survey, lifetime psychedelic use predicted self-reported pro-environmental behavior — an effect statistically explained by feeling more connected to nature. The study that opened the psychedelics–ecology research line.

Forstmann & Sagioglou · Journal of Psychopharmacology DOI 
Psilocybin End-of-life distress 2016

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

In a randomized double-blind crossover trial, a single high dose produced large, sustained reductions in depression and anxiety in cancer patients, with ~80% showing clinically significant response at six months.

Griffiths et al. · Journal of Psychopharmacology DOI 
Psilocybin End-of-life distress 2016

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer

The parallel NYU trial: a single psilocybin session with psychotherapy produced immediate and enduring reductions in cancer-related existential distress, mediated by mystical-type experience.

Ross et al. · Journal of Psychopharmacology DOI 
LSD Mechanism 2016

Neural correlates of the LSD experience revealed by multimodal neuroimaging

The first modern neuroimaging study of LSD: expanded visual cortex connectivity tracked hallucinations, while decreased default mode network integrity tracked ego dissolution.

Carhart-Harris et al. · PNAS DOI 
Ayahuasca Depression 2016

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression

An open-label SPECT study in recurrent depression: antidepressant effects appeared within hours and held across the 21-day observation, with corresponding changes in blood perfusion in mood-regulating brain regions. Small and uncontrolled, so it sets up the later randomised work rather than settling anything.

Sanches et al. · Journal of Clinical Psychopharmacology DOI 
General Safety 2016

Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences

Among ~2,000 people reporting their most difficult psilocybin experience: 39% rated it among the most challenging of their lives, yet 84% endorsed having benefited — difficulty and value are not opposites.

Carbonaro et al. · Journal of Psychopharmacology DOI 
General Epidemiology 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Population-level analysis of ~190,000 US adults: lifetime classic psychedelic use was associated with reduced psychological distress and suicidality — correlational, but contrary to the assumption of population harm.

Hendricks et al. · Journal of Psychopharmacology DOI 
Psilocybin Addiction 2014

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Small open-label pilot in long-term smokers: 80% biologically confirmed abstinence at six months — far above typical cessation outcomes — motivating the larger randomized trials that followed.

Johnson, Garcia-Romeu, Cosimano & Griffiths · Journal of Psychopharmacology DOI 
LSD Anxiety 2014

Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases

The first controlled LSD trial in over 40 years: LSD-assisted psychotherapy reduced anxiety in patients facing terminal illness, with benefits sustained at 12-month follow-up.

Gasser et al. · Journal of Nervous and Mental Disease DOI 
Ayahuasca Safety 2012

Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study

Long-term ceremonial users showed no evidence of psychopathology or cognitive impairment compared with matched non-users, and scored better on some measures — the main evidence that sustained ritual use is not inherently harmful.

Bouso et al. · PLoS ONE DOI 
Ketamine Bladder harm 2012

The prevalence and natural history of urinary symptoms among recreational ketamine users

Among 1,285 people who had used ketamine in the past year, recruited through a dance-music magazine, 26.6% reported urinary symptoms, and the more and the more often people used, the more likely they were. Of those who described their symptoms over time, 51% improved after stopping. Left to progress, ketamine bladder damage can become severe and irreversible, which is why early symptoms matter.

Winstock, Mitcheson, Gillatt & Cottrell · BJU International DOI 
MDMA PTSD 2011

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD

The first randomized controlled trial of MDMA-assisted therapy: 83% clinical response in treatment-resistant PTSD versus 25% with placebo, launching the two-decade path toward Phase 3.

Mithoefer et al. · Journal of Psychopharmacology DOI 
Salvia Safety 2011

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

The first controlled dose-response study of salvinorin A in humans: effects rose steeply with dose, peaked within about two minutes and resolved within roughly twenty, with no lasting cardiovascular or psychological harm at the doses tested.

Johnson et al. · Drug and Alcohol Dependence DOI 
General Drug policy 2010

Drug harms in the UK: a multicriteria decision analysis

The harm-ranking analysis: across sixteen harm criteria, psilocybin mushrooms and LSD ranked among the least harmful drugs assessed — while alcohol ranked most harmful overall.

Nutt, King & Phillips · The Lancet DOI 
General Safety 2008

Human hallucinogen research: guidelines for safety

The safety framework underlying every modern trial: screening criteria, preparation, session conduct, and follow-up. Read it to see what “supported conditions” means in practice.

Johnson, Richards & Griffiths · Journal of Psychopharmacology DOI 
Psilocybin Mystical experience 2006

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

The 2006 study that reopened modern psychedelic research: under supported conditions, a single high dose occasioned experiences participants ranked among the most meaningful of their lives, with benefits persisting at follow-up.

Griffiths, Richards, McCann & Jesse · Psychopharmacology DOI 
Ketamine Depression 2006

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

NIH replication in treatment-resistant depression: robust antidepressant effects within two hours of a single infusion, sustained for about a week — establishing ketamine’s clinical significance.

Zarate et al. · Archives of General Psychiatry DOI 
Ketamine Depression 2000

Antidepressant effects of ketamine in depressed patients

The serendipitous origin of rapid-acting antidepressants: a single sub-anesthetic ketamine infusion reduced depression within hours — an effect no conventional antidepressant produces.

Berman et al. · Biological Psychiatry DOI 
DMT Phenomenology 1994

Dose-response study of N,N-dimethyltryptamine in humans

The study that restarted US psychedelic research after a 20-year freeze: systematic characterization of intravenous DMT’s dose-dependent effects in healthy volunteers.

Strassman & Qualls · Archives of General Psychiatry DOI 

Harm reduction education only. Summaries simplify; always read the original paper before drawing conclusions.

This site provides harm reduction education only. Psychedelics are controlled substances in most jurisdictions.
Nothing here constitutes medical or legal advice. In crisis, see our crisis resources or contact a healthcare provider immediately.